nisamox tablets 50mg
norbrook laboratories limited - amoxicillin as amoxicillin trihydrate 40 mg, clavulanic acid 10.5 mg - tablet - dogs non food - amoxicillin and enzyme inhibitor
moxiclav 156.25mg/5ml powder for oral suspension
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - amoxicillin, clavulanic acid - powder for oral suspension - clavulanic acid 31.25 mg/5ml amoxicillin 125 mg/5ml - antibacterials for systemic use
clavucill 40mg/10mg, tablets for dogs and cats
v.m.d. n.v/s.a. - amoxicillin trihydrate; potassium clavulanate - tablet - 40, 10 mg/tablet - amoxicillin and enzyme inhibitor - dogs, cats - antibiotics
amoxicillin and clavulanate potassium tablet, film coated amoxicillin and clavulanate potassium powder, for suspension
dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 250 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–pro
clavudale 40 mg/10 mg tablets for cats and dogs
dechra regulatory b.v. - amoxicillin trihydrate; potassium clavulanate - tablet - 40, 10 mg/tablet - amoxicillin and enzyme inhibitor
cladaxxa 40 mg/10 mg chewable tablets for cats and dogs
krka, d.d., novo mesto - amoxicillin trihydrate; potassium clavulanate - chewable tablet - 40,10 mg/tablet - amoxicillin and enzyme inhibitor
twinox 40 mg/10 mg chewable tablets for cats and dogs
krka, d.d., novo mesto - amoxicillin trihydrate; potassium clavulanate - chewable tablet - 40,10 mg/tablet - amoxicillin and enzyme inhibitor
amoxicillin and clavulanate potassium tablet, film coated
proficient rx lp - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: limitations of use when susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium should not be used. usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is con
amoxicillin and clavulanate potassium tablet, coated amoxicillin and clavulanate potassium for suspension
usantibiotics, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: - lower respiratory tract infections - caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . - acute bacterial otitis media - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - sinusitis - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - skin and skin structure infections - caused by beta‑lactamase–producing isolates of staphylococcus aureus , escherichia coli , and klebsiella species. - urinary tract infections - caused by beta‑lactamase–producing isolates of e. coli , klebsiella species, and enterobacter species. limitations of use when susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium shou
amoxicillin/clavulanic acid sinochem dsm
dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate ; clavulanic acid (as potassium clavulanate, diluted : cellulose, microcrystalline(1:1)) - film coated tablet - 500/125 milligram - amoxicillin and enzyme inhibitor - : combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis